A. Zupa

发表

GSTM 1 and NAT 2 Polymorphisms and Colon , Lung and Bladder Cancer Risk : A Case-control Study

A. Cittadini, G. Torre, G. Improta, 2009 .

Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.

A. Capobianco, C. Tocchetti, G. Improta, 2013, Future oncology.

Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population: a case-control study.

A. Cittadini, G. Improta, A. Sgambato, 2011, Anticancer research.

Glutathione S-transferase (GST) polymorphisms as risk factors for cancer in a highly homogeneous population from southern Italy.

A. Cittadini, R. Galasso, A. Sgambato, 2002, Anticancer research.

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

G. Giaccone, E. Petricoin, L. Crinò, 2021, Journal for ImmunoTherapy of Cancer.

A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping

E. Petricoin, L. Liotta, J. Wulfkuhle, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients

V. Simeon, G. Storto, A. Nappi, 2015, Radiology and oncology.

GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.

G. La Torre, A. Cittadini, G. Improta, 2009, Anticancer research.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.

Alessandra Bulotta, Vanesa Gregorc, Vincenza Conteduca, 2013, Lung cancer.

Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC

M. Landriscina, G. Improta, M. Aieta, 2012, Medical Oncology.

Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma.

M. Martini, C. Piccoli, A. Cassano, 2014, Future oncology.

Inactivator media of sea bass (Dicentrarchus labrax L.) spermatozoa motility

A. Fabbrocini, G. Sansone, D. Matassino, 2001 .

Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity

P. Pedicini, F. Fraggetta, G. Improta, 2013, Oncology letters.

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma

M. Landriscina, G. Improta, M. Aieta, 2018, Medical Oncology.

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

E. Petricoin, L. Liotta, W. Broaddus, 2011, Journal of proteome research.

Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas

P. Zoppoli, G. Tortora, M. Basso, 2020, Cancers.

Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population.

G. La Torre, A. Cittadini, G. Improta, 2008, Anticancer research.

Low frequency of hCDC4 mutations in human primary ovarian cancer.

A. Cittadini, G. Scambia, V. Masciullo, 2007, Gynecologic oncology.

Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study.

E. Petricoin, L. Liotta, W. Broaddus, 2010 .